An oral, disease-modifying therapeutic for diabetic neuropathy — delivered through a proprietary sub-100nm nanocarrier system and a standardised clinical botanical matrix that neutralises the oxidative cascade driving peripheral nerve degeneration.
Earthpharm Technologies
Diabetic neuropathy progresses because of an oxidative cascade no single-molecule drug interrupts at its source. Our standardised clinical botanical matrix engages three regulatory nodes simultaneously — SIRT1, Nrf2 and AMPK — and is delivered through a proprietary sub-100nm nanocarrier system that crosses to the affected tissue.
Stage
TRL-3 · Preclinical
Phase
In-vivo entering
Delivery
Sub-100nm nanocarrier
Pathway
CDSCO · FDA 505(b)(2)
Institutional Residence
Earthpharm operates from the Bangalore Life Science Cluster as a resident bio-incubatee at C-CAMP — a Department of Biotechnology initiative that has supported over 450 deep-tech health startups — and is a member of the K-SAP BIO 50 2026 cohort. Work is conducted in affiliation with government R&D infrastructure across the Departments of Biotechnology and Textiles.
2026 cohort
Karnataka Startup Advancement Programme
Dept. of IT, BT & S&T, Government of Karnataka
Implementing institution · Resident bio-incubatee
Centre for Cellular and Molecular Platforms
Bangalore Life Science Cluster · DBT, Govt of India
Research affiliation
Central Sericultural Research & Training Institute
Ministry of Textiles, Government of India
The Unmet Need
Move your cursor across the field. Each clinical fact is silent until you attend to it — the same gesture our therapeutic asks of the disease itself.
How patients describe it
Sources — IDF Diabetes Atlas, 11th edition (2024) · NeuPSIG / IASP guidelines on neuropathic pain pharmacotherapy
The Team
Founding Team
Co-Founder & CEO
Previously commercial strategy at Meta (Facebook). Leads GTM across both commercialisation tracks, fundraising (SISFS, NSRCEL, SAMRIDH), and institutional partnerships.
Co-Founder & CSO
PhD, National Centre for Biological Sciences. Leads R&D direction, mechanistic validation (in-silico docking, in-vitro enzyme inhibition), and regulatory science for CDSCO Phytopharmaceutical and FDA 505(b)(2) pathways.
Co-Founder & COO
Leads upstream operations and supply chain — API and raw botanical sourcing, batch procurement across B1–B4, investor reporting, and operational lab logistics.
Scientific Execution
Lead Lab Scientist
Executes the wet-lab extraction protocols, the HPLC standardisation pipeline (six marker molecules across batches B1–B4), and the proprietary sub-100nm nano-encapsulation protocols for comparative bioavailability testing.
Advisory Counsel
Pharmaceutical Strategy & CMC
President & CEO · AVA Pharma Consultants
Three decades of CMC development across novel chemical entities and generics. Previously Vice President of Pharmaceutical Development & Quality at vTv Therapeutics, where lead candidates were progressed through IND, Phase 1, 2 and Phase 3; earlier, General Manager of Research at Torrent Pharma. PhD in Chemistry & Biochemistry (drug–DNA interactions), Seton Hall University.
Legal, IP & Regulatory Counsel
Founding Partner · Senior Advocate, Supreme Court of India
Chevening Scholar and graduate of Queen Mary University of London, specialised in Intellectual Property Law. Advises technology, healthcare and start-up clients on regulatory compliance, IP protection and contractual negotiation across IPR, medical law, and Technology-Media-Telecommunications. Represents clients at the Supreme Court of India, multiple high courts, the National Green Tribunal and arbitral institutions.